Manfred Rüdiger, Ariceum Therapeutics CEO (Presseportal)
June 8, 2022 03:00 AM EDTUpdated 09:39 AM
Financing
Startups

Ger­man start­up jumps in­to the hot ra­dio­phar­ma space with a for­mer Ipsen com­pound as lead pro­gram

Tyler Patchen

News Reporter

Ra­dio­phar­ma­ceu­ti­cals are con­tin­u­ing to be­come a hot top­ic in bio­phar­ma, with com­pa­nies such as Se­quoia, No­var­tis and Bris­tol My­ers Squibb look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times